Zydus Cadila gets USFDA nod for Chlorthalidone tablets to treat high BP
Zydus Cadila said Chlorthalidone tablets will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
New Delhi: Drug firm Zydus Cadila Monday said it has received the final nod from the US health regulator to market Chlorthalidone tablets, used to treat high blood pressure.
Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Chlorthalidone tablets in the strengths of 25 mg and 50 mg, the company said in a BSE filing.
Chlorthalidone is used to treat high blood pressure (hypertension). It is also used to treat fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver or kidney disorders or edema caused by taking steroids or estrogen.
Zydus Cadila said the product will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
The group now has 266 approvals and has filed over 350 abbreviated new drug applications (ANDAs) since the commencement of its filing process, Zydus Cadila said.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at email@example.com Contact no. 011-43720751 To know about our editorial team click here